CAS Number: 1629229-37-3

Stage: Pipeline

Fezolinetant is a first-in-class, non-hormonal neurokinin-3 (NK3) receptor antagonist developed for the management of moderate to severe vasomotor symptoms (VMS) associated with menopause, such as hot flashes and night sweats. By targeting the KNDy neurons in the hypothalamus—responsible for thermoregulation—Fezolinetant helps restore temperature control without the use of estrogen or progestin. It provides a much-needed alternative for women who are contraindicated for hormone replacement therapy or prefer non-hormonal options. With a favorable safety and efficacy profile, Fezolinetant is poised to redefine treatment standards in women’s health.

Explore Royal Pharma as your potential partner for Fezolinetant API.